Immunogenicity of A 23-Valent Pneumococcal Polysaccharide Vaccine Among Mexican Children

Background and Aims Streptococcus pneumoniae infection continues to be a major source of morbidity and mortality in children in Mexico. The aim of this study was to evaluate the immune response to six serotypes in children <5 years of age after immunization with a 23-valent pneumococcal polysacch...

Full description

Saved in:
Bibliographic Details
Published inArchives of medical research Vol. 43; no. 5; pp. 402 - 405
Main Authors Espinosa-Padilla, Sara Elva, Murata, Chiharu, Estrada-Parra, Sergio, Santos-Argumedo, Leopoldo, Mascareñas, Cesar, Franco-Paredes, Carlos, Espinosa-Rosales, Francisco Javier
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.07.2012
Subjects
Age
Antibodies, Bacterial - blood
Child, Preschool
Children
Humans
Immune response
Immunization
Immunogenicity
Immunoglobulin G - blood
Infant
Infection
Internal Medicine
Morbidity
Mortality
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines - administration & dosage
Pneumococcal Vaccines - adverse effects
Pneumococcal Vaccines - immunology
Polysaccharide
Polysaccharides
Polysaccharides, Bacterial - administration & dosage
Polysaccharides, Bacterial - adverse effects
Polysaccharides, Bacterial - immunology
Prospective Studies
Serotypes
Streptococcus pneumoniae
Streptococcus pneumoniae - immunology
Vaccination
Vaccine
Vaccines
Vaccine
Immunogenicity
Polysaccharide
Streptococcus pneumoniae
Online AccessGet full text

Cover

More Information
Summary:Background and Aims Streptococcus pneumoniae infection continues to be a major source of morbidity and mortality in children in Mexico. The aim of this study was to evaluate the immune response to six serotypes in children <5 years of age after immunization with a 23-valent pneumococcal polysaccharide vaccine. Methods A prospective study was conducted among children aged from 18 months to 4 years. Pre- and postvaccination titers for the serotypes selected in this project demonstrate a substantial response among all age groups. Results We identified mild adverse events in 62% of the participants in this study. No serious adverse events were reported during the study. Conclusions Pneumococcal polysaccharide vaccine produced adequate immunogenicity in all age groups evaluated.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
ObjectType-Feature-1
ISSN:0188-4409
1873-5487
DOI:10.1016/j.arcmed.2012.07.005